Evidence map›Paper›PMID 29982557›Full record

ArticleThe Journal of infectious diseases2018

Compatibility of Maximum-Containment Virus-Inactivation Protocols With Identification of Bacterial Coinfections by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.

M Jeremiah Matson, Frida Stock, W Lesley Shupert, Trenton Bushmaker, Friederike Feldmann, Wendy B Bishop, Karen M Frank, John P Dekker, Daniel S Chertow, Vincent J Munster

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Pathogens (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

M Jeremiah MatsonMarshall University Joan C. Edwards School of Medicine, Huntington, West Virginia.
Frida StockClinical Center, National Institutes of Health, Bethesda, Maryland.
W Lesley ShupertNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Trenton BushmakerNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Friederike FeldmannNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
Wendy B BishopClinical Center, National Institutes of Health, Bethesda, Maryland.
Karen M FrankClinical Center, National Institutes of Health, Bethesda, Maryland.
John P DekkerClinical Center, National Institutes of Health, Bethesda, Maryland.
Daniel S ChertowClinical Center, National Institutes of Health, Bethesda, Maryland.
Vincent J MunsterNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.

Funding

Virus Ecology UnitZIAAI001179 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MUNSTER, VINCENT · 2013 to 2025
$24.3M
International Research in CongoZIAAI001190 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MUNSTER, VINCENT · 2014 to 2025
$3.4M
Novel Applications of Mass Spectrometry and Proteomics to Infectious Disease DiagnosticsZIAAI001252 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DEKKER, JOHN · 2019 to 2020
$742k
Clinical and Molecular Features of Ebola Virus DiseaseZIACL009024 · CLC · CLINICAL CENTER · PI CHERTOW, DANIEL S · 2017 to 2025
$0k
Novel Applications of Mass Spectrometry and Proteomics to Infectious Disease DiagnosticsZIACL080019 · CLC · CLINICAL CENTER · PI DEKKER, JOHN · 2014 to 2018
$0k
6 · The paper itself

Abstract

Diagnostics and research analyses involving samples containing maximum-containment viruses present unique challenges, and inactivation protocols compatible with downstream testing are needed. Our aim was to identify a validated viral inactivation protocol compatible with bacterial identification by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). We assessed a panel of bacteria with 6 validated maximum-containment virus-inactivation protocols and report that inactivation with TRIzol or γ-irradiation is compatible with MALDI-TOF MS. The availability, simplicity, and rapidity of TRIzol inactivation make this method the more suitable choice.

Indexed as

BacteriaCoinfectionHumansSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationVirusesVirus Inactivation

Identifiers

PMID29982557
PMCPMC6249573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.